Nicoletta Machin is an Oncology physician affiliated with University of Pittsburgh. OpenAlex indexes 37 publications with 386 citations (h-index 9); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders
Sponsor: Nicoletta C Machin
- Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Sponsor: Nicoletta C Machin
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20252 payments
- Diagnostica Stago SASProgram year20251 payment
- Stryker CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
87.9%Factor Xa inhibitor51.7%Fondaparinux Sodium48%Eliquis27%Xarelto25%Part D<11 patientsVitamin K antagonist21.6%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
12.1%Antimetabolite12.1%Hydroxyurea100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- OC 63.2 Bleeding Disorder of Unknown Cause (BDUC): A National Practice Survey of US Hemophilia Treatment Centers
Research and Practice in Thrombosis and Haemostasis
2026 - PB3420 Qualitative Study Exploring the Lived Experiences of Adolescents and Adults with von Willebrand Disease Treated with VGA039 and Their Families in the VIVID-3 Phase 1/2 Clinical Study
Research and Practice in Thrombosis and Haemostasis
2026 - OC 32.3 Subcutaneous Four-Week Dosing of the Novel Protein S Antibody VGA039 Demonstrates Safety and Clinically Meaningful Bleed Reduction in Patients with Von Willebrand Disease: Phase 1/2 Multi-Dose Study Results
Research and Practice in Thrombosis and Haemostasis
2026 - PB1496 Single center chart review of Hemophilia A patients with prior inhibitors treated with recombinant Factor VIII Efanesoctocog alfa to assess inhibitor recurrence
Research and Practice in Thrombosis and Haemostasis
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Norman Wolmark, MD
University of Pittsburgh
Sally Wenzel, MD
University of Pittsburgh
Mary Phillips, MD
University of Pittsburgh
Udai Kammula, MD
University of Pittsburgh
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”